Zantac Recalled Due to Potential Cancer Risk
On April 1, 2019, the Food and Drug Administration (FDA) recalled all prescription and over-the-counter Zantac (Ranitidine) drugs from the market. This was the latest step in a long running investigation related to contaminated Zantac. The FDA determined that the contaminate known as N-Nitrosodimethylamine (NDMA) increased over time and when stored at room temperatures may expose consumers to unacceptable levels of NDMA.
NDMA is a known human carcinogen – meaning is could cause cancer. Lawsuits claim that Zantac cause the following types of cancer:
- Bladder Cancer
- Colorectal Cancer
- Esophageal Cancer
- Intestinal Cancer
- Kidney Cancer
- Liver Cancer
- Pancreatic Cancer
- Stomach Cancer
- Testicular Cancer
- Uterine or Ovarian Cancer
Yaeger Law is investigating cases in which patients took Zantac or generic forms of Rantidine and then developed certain cancers. If you or a loved one experienced injuries related to Zantac, you may be entitled to compensation. Contact Yaeger Law to discuss the details of your potential Zantac Lawsuit.
TIMELINE OF RECALLS:
11/19/2019: Precision Dose recalls ranitidine oral solution, USP 150 mg/10 ml due to potential presence of n-nitrosodimethylamine (NDMA) above levels established by the FDA.
11/15/2019: Golden State Medical Supply (GSMS, Inc.) recalls ranitidine HCl 150mg and 300mg capsules due to potential presence of n-nitrosodimethylamine (NDMA) above levels established by the FDA.
11/8/2019: Amneal Pharmaceuticals recalls ranitidine tablets, 150 mg and 300 mg, and ranitidine syrup (ranitidine oral solution, USP), 15 mg/ml due to due to potential n-nitrosodimethylamine (NDMA) amounts above levels established by the FDA.
11/8/2019: American Health Packaging recalls ranitidine liquid unit dose cups due to NDMA impurity.
11/6/2019: Aurobindo & DG Health recalls ranitidine due to NDMA impurity.
10/25/2019: Novitium Pharma recalls ranitidine hydrochloride capsules 150 mg and 300 mg because it may contain n-nitrosodimethylamine (NDMA).
10/25/2019: Lannett Company, Inc. recalls ranitidine syrup (ranitidine oral solution, USP), 15mg/ml due to above levels of NDMA.
10/23/2019: Dr. Reddy’s, Kroger, Walgreens, and others recall ranitidine tablets & capsules for containing N-Nitrosodimethylamine (NDMA).
10/23/2019: Perrigo Company plc recalls Ranitidine (all pack sizes) for the presence of N-Nitrosodimethylamine (NDMA).
10/22/2019: Sanofi recalls all Zantac OTC products in the U.S. for possibly containing N-Nitrosodimethylamine (NDMA).
9/25/2019: Apotex Corp. recalls 75mg and 150mg ranitidine tablets for containing a nitrosamine impurity called N-nitrosodimethylamine (NDMA)
9/23/2019: Sandoz Inc. recalled ranitidine hydrochloride capsules due to an elevated amount of an unexpected impurity, N-nitrosodimethylamine (NDMA)